

Q13

148. (new) The polypeptide of claim 147, wherein the population of cancer cells comprises a cancer cell line selected from: a leukemia cell line, a melanoma cell line, a lung cancer cell line, a colon cancer cell line, a CNS cancer cell line, an ovarian cancer cell line, a breast cancer cell line, a prostate cancer cell line, and a renal cancer cell line, the growth inhibition activity measured as the concentration of polypeptide or human interferon-alpha 2a causing a 50% inhibition of growth of the cell line (GI50 value), wherein the polypeptide has a GI50 value at least 2-fold lower than the GI50 value of the human interferon-alpha 2a.

#### REMARKS


No new matter has been added to the application by way of the above amendments to the specification and claims. Amendment to the specification is made to correct citations and typographical errors. Claim 4 has also been amended simply to correct a typographical error. The remainder of the amendments and new claims are submitted to conform the claims to U.S. practice with respect to claim dependency.

#### CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 510-337-7871.

LAW OFFICES OF  
JONATHAN ALAN QUINE  
P.O. BOX 458  
Alameda, CA 94501  
(510) 337-7871  
Fax (510) 337-7877

Respectfully submitted,

  
Gwynedd Warren, Ph.D.  
Reg. No. 45,200